Commitments and Contingencies

12 Months Ended

Dec. 31, 2013

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. Commitments and Contingencies

Facility Lease

The Company has amended its current facility lease to extend the term to June 30, 2014 and adjust the base monthly rent from July 1, 2013 to June 30, 2014 to $16,616. The lease is for a total of 5,275 square feet of office space located in South San Francisco, California. Rent expense for the years ended December 31, 2013, 2012 and 2011 was $212,473, $516,257 and $582,676 respectively.

Manufacturing Commitments

The Company has begun initial drug manufacturing activities associated with the potential EMA filing for a European Marketing Authorization for ZYBRESTAT^® in ATC. As of December 31, 2013, the Company has a balance of unapplied purchase orders for expenditures related to drug manufacturing activities of approximately $2,077,000, of which approximately $162,000 was estimated and accrued at December 31, 2013 for services performed, leaving approximately $1,345,000 to be incurred. Of the $1,345,000 to be incurred, the Company expects to incur approximately $1,260,000 over the next twelve months, of which approximately $570,000 is committed under non-cancelable contracts.

The following table presents information regarding our contractual obligations as of December 31, 2013 in thousands:

	2014		2015		2016		2017		2018 and thereafter		Total
Clinical development and related commitments	$	590	$	20	$	—	$	—	$	—	$	610
Operating leases		100		—		—		—		—		100
Total contractual obligations	$	690	$	20	$	—	$	—	$	—	$	710

Clinical development and related commitments include certain contractual obligations under contracts related to clinical activities.